ClinVar Miner

Submissions for variant NM_001005242.3(PKP2):c.1211dup (p.Val406fs)

dbSNP: rs397516989
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000038154 SCV000061820 pathogenic Arrhythmogenic right ventricular cardiomyopathy 2019-01-18 criteria provided, single submitter clinical testing The p.Val406SerfsX4 variant in PKP2 has been identified in >15 individuals with ARVC, the majority of whom were Dutch (van Tintelen 2006, Groeneweg 2013, Orgero n 2017, Proost 2017, Walsh 2017, LMM data). It was also identified in the homozy gous state in 2 siblings with hypoplastic left heart syndrome (Verhagen 2018). I t was absent from large population studies. This variant is predicted to cause a frameshift, which alters the protein?s amino acid sequence beginning at positio n 406 and leads to a premature termination codon 4 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of f unction of the PKP2 gene is an established disease mechanism in autosomal domina nt ARVC. In summary, this variant meets criteria to be classified as pathogenic for autosomal dominant ARVC. ACMG/AMP criteria applied: PVS1, PS4, PM2.
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center RCV000603676 SCV000744702 pathogenic Arrhythmogenic right ventricular dysplasia 9 2015-09-21 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001841581 SCV000920004 pathogenic Cardiac arrhythmia 2017-11-15 criteria provided, single submitter clinical testing Variant summary: The PKP2 c.1211dupT (p.Val406SerfsX4) variant results in a premature termination codon, predicted to cause a truncated or absent PKP2 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g. c.1613G>A/ p.Trp538X). One in silico tool predicts a damaging outcome for this variant. This variant is absent in 246050 control chromosomes. This variant has been reported in multiple confirmed ARVD patients, some of whom have a strong family history. Taken together, this variant is classified as pathogenic.
Invitae RCV000603676 SCV000959255 pathogenic Arrhythmogenic right ventricular dysplasia 9 2023-09-27 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Val406Serfs*4) in the PKP2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in PKP2 are known to be pathogenic (PMID: 15489853, 23911551). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individuals with arrhythmogenic rightventricular dysplasia/cardiomyopathy and arrhythmogenic right ventricular dysplasia/cardiomyopathy (PMID: 16567567, 23871674, 27532257). It has also been observed to segregate with disease in related individuals. This variant is also known as 1211–1212insT (Val406SerfsX3) and c.1211dup p.(Val406fs). ClinVar contains an entry for this variant (Variation ID: 45015). For these reasons, this variant has been classified as Pathogenic.
MGZ Medical Genetics Center RCV000603676 SCV002580541 pathogenic Arrhythmogenic right ventricular dysplasia 9 2021-12-28 criteria provided, single submitter clinical testing
Ambry Genetics RCV002354195 SCV002653355 pathogenic Cardiovascular phenotype 2023-03-29 criteria provided, single submitter clinical testing The c.1211dupT pathogenic mutation, located in coding exon 5 of the PKP2 gene, results from a duplication of T at nucleotide position 1211, causing a translational frameshift with a predicted alternate stop codon (p.V406Sfs*4). This alteration has been reported in subjects with arrhythmogenic right ventricular cardiomyopathy (ARVC) (van Tintelen JP et al. Circulation, 2006 Apr;113:1650-8; Xu T et al. J. Am. Coll. Cardiol., 2010 Feb;55:587-97; Walsh R et al. Genet. Med., 2017 02;19:192-203). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
CeGaT Center for Human Genetics Tuebingen RCV001699188 SCV002821690 pathogenic not provided 2022-11-01 criteria provided, single submitter clinical testing PKP2: PVS1, PM2
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen RCV000603676 SCV000733163 pathogenic Arrhythmogenic right ventricular dysplasia 9 no assertion criteria provided clinical testing
Clinical Genetics, Academic Medical Center RCV001699188 SCV001918289 pathogenic not provided no assertion criteria provided clinical testing
Genome Diagnostics Laboratory, University Medical Center Utrecht RCV001699188 SCV001926794 pathogenic not provided no assertion criteria provided clinical testing
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ RCV001699188 SCV001958211 pathogenic not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.